phenotype targeting

BrYet is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment and cure of otherwise incurable cancers, particularly metastatic cancers of the lungs and liver. It targets cancer-specific molecular transport phenotypes using multi-component therapeutics. Its first drug, ML-016, has demonstrated functional cures in preclinical animal models. Its research is protected by a patent portfolio, some licensed from Houston Methodist Research Institute and University of Texas Health Science Center at Houston.

Read more

drug developmentpreclinical research